Trevi Therapeutics, Inc. (TRVI)
13.14
-0.04
(-0.30%)
USD |
NASDAQ |
Oct 07, 16:00
13.42
+0.28
(+2.13%)
After-Hours: 06:17
Trevi Therapeutics Enterprise Value : 1.553B for Oct. 7, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 07, 2026 | 1.553B |
| October 06, 2026 | 1.559B |
| October 05, 2026 | 1.636B |
| October 02, 2026 | 1.663B |
| October 01, 2026 | 1.701B |
| September 30, 2026 | 1.721B |
| September 29, 2026 | 1.735B |
| September 28, 2026 | 1.733B |
| September 25, 2026 | 1.734B |
| September 24, 2026 | 1.772B |
| September 23, 2026 | 1.741B |
| September 22, 2026 | 1.852B |
| September 21, 2026 | 1.802B |
| September 18, 2026 | 1.811B |
| September 17, 2026 | 1.848B |
| September 16, 2026 | 1.819B |
| September 15, 2026 | 1.824B |
| September 14, 2026 | 1.945B |
| September 11, 2026 | 1.946B |
| September 10, 2026 | 1.948B |
| September 09, 2026 | 2.052B |
| September 08, 2026 | 2.077B |
| September 04, 2026 | 2.140B |
| September 03, 2026 | 2.111B |
| September 02, 2026 | 2.110B |
| Date | Value |
|---|---|
| September 01, 2026 | 2.042B |
| August 31, 2026 | 2.046B |
| August 28, 2026 | 2.073B |
| August 27, 2026 | 2.240B |
| August 26, 2026 | 2.234B |
| August 25, 2026 | 2.238B |
| August 24, 2026 | 2.257B |
| August 21, 2026 | 2.240B |
| August 20, 2026 | 2.281B |
| August 19, 2026 | 2.361B |
| August 18, 2026 | 2.365B |
| August 17, 2026 | 2.314B |
| August 14, 2026 | 2.311B |
| August 13, 2026 | 2.267B |
| August 12, 2026 | 2.207B |
| August 11, 2026 | 2.217B |
| August 10, 2026 | 2.217B |
| August 07, 2026 | 2.318B |
| August 06, 2026 | 2.317B |
| August 05, 2026 | 2.338B |
| August 04, 2026 | 2.352B |
| August 03, 2026 | 2.231B |
| July 31, 2026 | 2.281B |
| July 30, 2026 | 2.302B |
| July 29, 2026 | 2.258B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.887B |
| Corcept Therapeutics, Inc. | 12.61B |
| Veru, Inc. | 18.84M |
| Johnson & Johnson | 650.68B |
| Eli Lilly & Co. | 1.165T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -17.80M |
| Total Expenses (Quarterly) | 17.80M |
| EPS Diluted (Quarterly) | -0.1136 |
| Earnings Yield | -2.61% |
| Normalized Earnings Yield | -2.608 |